Patents Assigned to Genentech
  • PYRIMIDINYL-PYRIDYLOXY-NAPHTHYL COMPOUNDS AND METHODS OF TREATING IRE1-RELATED DISEASES AND DISORDERS
    Publication number: 20180265497
    Abstract: Described herein are pyrimidinyl-pyridyloxy-naphthyl compounds with inositol requiring enzyme 1 (IRE1) modulation activity or function having the Formula I or I? structure: or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I or I? compounds, as well as methods of using such IRE1 modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.
    Type: Application
    Filed: May 24, 2018
    Publication date: September 20, 2018
    Applicants: Genentech, Inc., The Regents of the University of California
    Inventors: Marie-Gabrielle Braun, Paul Gibbons, Wendy Lee, Cuong Ly, Joachim Rudolph, Jacob Schwarz, Avi Ashkenazi, Leo Fu, Tommy Lai, Fei Wang, Ramsay Beveridge, Liang Zhao
  • THERAPEUTIC COMPOUNDS AND COMPOSITIONS, AND METHODS OF USE THEREOF
    Publication number: 20180265515
    Abstract: Compounds of Formula (00A) and salts thereof, wherein R1, R2 R3, R4 and n are defined herein, are useful as inhibitors of one or more Janus kinases. Also provided are pharmaceutical compositions that include a compound of Formula (00A) and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient.
    Type: Application
    Filed: May 22, 2018
    Publication date: September 20, 2018
    Applicant: Genentech, Inc.
    Inventors: Yun-Xing Cheng, Paul Gibbons, Terry Kellar, Wei Li, Rohan Mendonca, Po-wai Yuen, Mark Edward Zak, Lei Zhang
  • TREATMENT OF AUTOIMMUNE DISEASES
    Publication number: 20180264107
    Abstract: The present invention concerns treatment of autoimmune diseases with antagonists which bind to B cell surface markers, such as CD19 or CD20.
    Type: Application
    Filed: May 17, 2018
    Publication date: September 20, 2018
    Applicants: Genentech, Inc., Biogen Inc.
    Inventors: John G. Curd, Antonio J. Grillo-Lopez, Lori A. Kunkel
  • THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF
    Publication number: 20180265465
    Abstract: The invention provides compounds having the general Formula (I); and pharmaceutically acceptable salts thereof; wherein the variables RA, RAA, subscript n, subscript q, ring A, X2, L, subscript m, X1, R1, R2, R3, R4, R5, D and E have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.
    Type: Application
    Filed: May 24, 2018
    Publication date: September 20, 2018
    Applicants: GENENTECH, INC., XENON PHARMACEUTICALS INC.
    Inventors: Jean-Christophe ANDREZ, Philippe BERGERON, Paul Robert BICHLER, Sultan CHOWDHURY, Christoph Martin DEHNHARDT, Thilo FOCKEN, Wei GONG, Michael Edward GRIMWOOD, Abid HASAN, Ivan William HEMEON, Qi JIA, Brian SAFINA, Shaoyi SUN, Michael Scott WILSON, Alla Yurevna ZENOVA
  • ARYL SULTAM DERIVATIVES AS RORc MODULATORS
    Publication number: 20180263996
    Abstract: Compounds of the formula I: or a pharmaceutical salt thereof, wherein p, s, A, R3 and Re are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis.
    Type: Application
    Filed: December 19, 2017
    Publication date: September 20, 2018
    Applicant: Genentech, Inc.
    Inventors: Olivier RENE, Benjamin FAUBER, David VESEY, Paul WINSHIP, Tammy LADDUWAHETTY
  • CELL-BASED ASSAY FOR DETECTING ANTI-CD3 HOMODIMERS
    Publication number: 20180267055
    Abstract: The present invention provides a cell-based assay for identifying and/or quantifying anti-CD3 homodimers in a composition comprising a T cell-dependent Bispecific antibody (TDB). In some aspects, the invention T cells comprising a T cell activation responsive reporter are contacted with the TDB to detect the presence of anti-CD3 homodimers. Compositions of reporter T cells and kits are also contemplated.
    Type: Application
    Filed: November 28, 2017
    Publication date: September 20, 2018
    Applicant: Genentech, Inc.
    Inventor: Kendall CAREY
  • Cysteine engineered antibodies and conjugates
    Patent number: 10077318
    Abstract: Cysteine engineered antibodies comprising a free cysteine amino acid in the heavy chain or light chain are prepared by mutagenizing a nucleic acid sequence of a parent antibody and replacing one or more amino acid residues by cysteine to encode the cysteine engineered antibody; expressing the cysteine engineered antibody; and isolating the cysteine engineered antibody.
    Type: Grant
    Filed: September 11, 2015
    Date of Patent: September 18, 2018
    Assignee: Genentech, Inc.
    Inventors: Sunil Bhakta, Hans Erickson, Jagath R. Junutula, Katherine Kozak, Rachana Ohri, Thomas Pillow
  • Deuterated compounds and uses thereof
    Patent number: 10076581
    Abstract: The present invention relates to deuterated and optionally detectably labeled compounds of formula (I) and formula (V): and salts thereof, wherein R1, R2, A, and X10-X19 have any of the values defined in the specification. Also included are pharmaceutical compositions comprising such compounds and salts, and methods of using such compounds and salts as imaging agents.
    Type: Grant
    Filed: January 26, 2016
    Date of Patent: September 18, 2018
    Assignee: Genentech, Inc.
    Inventors: Jan Marik, Joseph P. Lyssikatos, Simon Williams
  • PROCESS FOR MAKING HYDROXYLATED CYCLOPENTYLPYRIMIDINE COMPOUNDS
    Publication number: 20180258054
    Abstract: The invention provides processes for preparing a compound of formula I and salts thereof, wherein R1 is defined herein, and compounds and intermediates of said formula.
    Type: Application
    Filed: October 12, 2017
    Publication date: September 13, 2018
    Applicants: Array BioPharma Inc., Genentech, Inc.
    Inventors: David Askin, Chong Han, Jonathan W. Lane, Travis Remarchuk, Sagar Shakya, C. Gregory Sowell, Keith L. Spencer, Peter J. Stengel
  • PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING
    Publication number: 20180258043
    Abstract: The invention provides novel inhibitors of hedgehog signaling that are useful as a therapeutic agents for treating malignancies where the compounds have the general formula I: wherein A, X, Y R1, R2, R3, R4, m and n are as described herein.
    Type: Application
    Filed: March 7, 2018
    Publication date: September 13, 2018
    Applicants: GENENTECH, INC., CURIS, INC.
    Inventors: Janet L. GUNZNER-TOSTE, Daniel P. SUTHERLIN, Mark S. STANLEY, Liang BAO, Georgette M. CASTANEDO, Rebecca L. LALONDE, Shumei WANG, Mark E. REYNOLDS, Scott J. SAVAGE, Kimberly MALESKY, Michael S. DINA, Michael F.T. KOEHLER
  • METHODS OF TREATING CANCER USING ANTI-OX40 ANTIBODIES AND PD-1 AXIS BINDING ANTAGONISTS
    Publication number: 20180256711
    Abstract: The invention provides methods of treating or delaying progression of cancer in an individual comprising administering to the individual an anti-human OX40 agonist antibody and an anti-PDL1 antibody. In some embodiments, the anti-human OX40 agonist antibody is administered in a dose selected from about 0.8 mg, about 3.2 mg, about 12 mg, about 40 mg, about 80 mg, about 130 mg, about 160 mg, about 300 mg, about 320 mg, about 400 mg, about 600 mg, and about 1200 mg, and the anti-PDL1 antibody is administered at a dose of about 800 mg or about 1200 mg.
    Type: Application
    Filed: December 14, 2017
    Publication date: September 13, 2018
    Applicant: Genentech, Inc.
    Inventors: Ina P. RHEE, Jeong KIM, Mahrukh HUSENI, Eric STEFANICH, Siddharth SUKUMARAN, Chi-Chung LI
  • METHODS OF TREATING CANCER USING B-RAF INHIBITORS AND IMMUNE CHECKPOINT INHIBITORS
    Publication number: 20180256552
    Abstract: Provided herein are therapies including dosage regimens for the treatment of cancer using B-RAF and an immune checkpoint inhibitor in combination with and/or without a MEK inhibitor.
    Type: Application
    Filed: May 18, 2018
    Publication date: September 13, 2018
    Applicant: Genentech, Inc.
    Inventors: Dawn Colburn, Nicole Richie
  • Ultrapurified DsbA and DsbC and methods of making and using the same
    Patent number: 10073098
    Abstract: The present invention provides methods for producing disulfide oxidoreductase A (DsbA) and disulfide oxidoreductase C (DsbC) polypeptides at very high levels of purity. Also provided are ultrapure DsbA and DsbC and methods of using same, e.g., for use in immunoassays to show removal of DsbA and DsbC from biologics produced in bacteria.
    Type: Grant
    Filed: March 4, 2016
    Date of Patent: September 11, 2018
    Assignee: Genentech, Inc.
    Inventors: Marc Wong, Liliana T. Yee, Amy Lim, Chris B. Fong
  • Optimized variants of anti-VEGF antibodies and methods of treatment thereof by reducing or inhibiting angiogenesis
    Patent number: 10072075
    Abstract: The present invention provides anti-VEGF antibodies and compositions that include anti-VEGF antibodies (e.g., antibody conjugates, fusion proteins, and polymeric formulations), and uses thereof, for example for treatment of disorders associated with pathological angiogenesis. The present invention also provides methods of identifying antibody variants with improved properties, for example, enhanced binding affinity, stability, pharmacokinetics, and/or expression.
    Type: Grant
    Filed: September 23, 2016
    Date of Patent: September 11, 2018
    Assignee: Genentech, Inc.
    Inventors: Patrick Koenig, Chingwei Vivian Lee, Karthikan Rajagopal, Amin Famili, Germaine Fuh
  • N-substituted benzamides and methods of use thereof
    Patent number: 10071957
    Abstract: The invention provides novel compounds having the general formula (I) and pharmaceutically acceptable salts thereof, wherein the variables RA, subscript n, ring A, X2, L, subscript m, X1, ring D, R1, and RN have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.
    Type: Grant
    Filed: July 5, 2013
    Date of Patent: September 11, 2018
    Assignees: GENENTECH, INC., XENON PHARMACEUTICALS INC.
    Inventors: Christoph Martin Dehnhardt, Sultan Chowdhury, Thilo Focken, Michael Edward Grimwood, Ivan William Hemeon, Brian Safina, Daniel P. Sutherlin
  • COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR
    Publication number: 20180251567
    Abstract: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Application
    Filed: May 18, 2018
    Publication date: September 6, 2018
    Applicant: Genentech, Inc.
    Inventors: Mark Dennis, Bonnee Rubinfeld, Paul Polakis
  • ADJUVANT TREATMENT OF HER2-POSITIVE BREAST CANCER
    Publication number: 20180250397
    Abstract: Methods are provided for the adjuvant treatment of operable HER2-positive primary breast cancer in human patients by administration of pertuzumab in addition to chemotherapy and trastuzumab. The methods reduce the risk of recurrence of invasive breast cancer or death for a patient diagnosed with HER2-positive early breast cancer (eBC) compared to administration of trastuzumab and chemotherapy, without pertuzumab.
    Type: Application
    Filed: February 28, 2018
    Publication date: September 6, 2018
    Applicants: Genentech, Inc., F. Hoffmann-La Roche AG
    Inventors: Mark C. BENYUNES, Graham Alexander ROSS
  • METHODS OF TREATING HER2-POSITIVE CANCER
    Publication number: 20180251557
    Abstract: Methods of treating patients having HER2-positive cancer are provided. Certain methods involve treatment of HER2 positive breast cancer using a programmed cell death protein 1 (PD-1) binding antagonist or a programmed death ligand 1 (PD-L1) binding antagonist in combination with trastuzumab and pertuzumab or with trastuzumab emtansine. The treatment regimen may be used in various clinical settings, for example, for treatment in the neoadjuvant or metastatic setting.
    Type: Application
    Filed: May 15, 2018
    Publication date: September 6, 2018
    Applicant: GENENTECH, INC.
    Inventors: Stephen Chui, Melanie Smitt, Monika Patre
  • MIT BIOMARKERS AND METHODS USING THE SAME
    Publication number: 20180250394
    Abstract: Provided are therapies related to the treatment of pathological conditions, such as cancer.
    Type: Application
    Filed: December 8, 2016
    Publication date: September 6, 2018
    Applicant: Genentech, Inc.
    Inventors: Steffen Durinck, Bijay Jaiswal, Zora Modrusan, Somasekar Seshagiri, Eric Stawiski, Na Zhang
  • Tricyclic PI3K inhibitor compounds and methods of use
    Patent number: 10065970
    Abstract: Described herein are tricyclic compounds with phosphoinositide-3 kinase (PI3K) modulation activity or function having the Formula I structure: or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such PI3K modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon PI3K dysregulation.
    Type: Grant
    Filed: September 7, 2016
    Date of Patent: September 4, 2018
    Assignee: Genentech, Inc.
    Inventors: Marie-Gabrielle Braun, Keira Garland, Emily Hanan, Hans Purkey, Steven T. Staben, Robert Andrew Heald, Jamie Knight, Calum Macleod, Aijun Lu, Guosheng Wu, Siew Kuen Yeap